AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26001387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23901669 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (Avastin)
Number of subjects: 150
Study 22789792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (inhalation group or aromatherapy hand technique) with essential oil blend of rose otto and lavandula angustifolia @ 2% dilution, 15 min sessions, twice a week for four weeks
Number of subjects: 28
Study 22789792 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-randomized, instructed to avoid aromatherapy)
Number of subjects: 28
Study 19165115 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment for 2 weeks
Number of subjects: 19
Study 17565326 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction with tacrolimus monotherapy
Number of subjects: 21
Study 17565326 — intervention group
Group type: COMPARATOR
Intervention: Thymoglobulin induction with tacrolimus, mycophenolate, and steroids
Number of subjects: 21
Study 15030964 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight stabilisation (<= 1 kg lost) after an 8 week nutrition intervention
Number of subjects: 107
Study 15030964 — intervention group
Group type: COMPARATOR
Intervention: Weight losing (> 1 kg lost)
Number of subjects: 107
Study 11473908 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster‐Stratton basic videotape programme administered to parents of six to eight children over 13‐16 weeks
Number of subjects: 141
Study 11473908 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 141
Study 11473908 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster‐Stratton basic videotape programme
Number of subjects: 141
Study 9870319 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) monotherapy
Number of subjects: 0
Study 9870319 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine (ZDV + ddI)
Number of subjects: 0
Study 9870319 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) alone
Number of subjects: 0
Study 9870319 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) therapy duration
Number of subjects: 0
Study 9870319 — intervention group
Group type: COMPARATOR
Intervention: Viral burden measurement
Number of subjects: 0
Study 7851513 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the motor cortex
Number of subjects: 12
Study 7851513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical stimulation
Number of subjects: 12
Study 7851513 — intervention group
Group type: COMPARATOR
Intervention: Cortical stimulation in patients with complete Bell's palsy
Number of subjects: 12
Study 3132574 — intervention group
Group type: EXPERIMENTAL
Intervention: met‐hGH in postabsorptive state
Number of subjects: 10
Study 3132574 — intervention group
Group type: EXPERIMENTAL
Intervention: met‐hGH in intravenous feeding
Number of subjects: 10
Study 31599561 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hypocalcemia (<8.5 mg/dL)
Number of subjects: 285
Study 31599561 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypocalcemia (<7.5 mg/dL)
Number of subjects: 285
Study 31599561 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 285
Study 31599561 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer operative time
Number of subjects: 285
Study 31599561 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative calcium and magnesium levels correlation
Number of subjects: 285
Study 28665377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture treatment with anti-homotoxic agents (placental compositum, co-enzyme compositum, ubichinon compositum)
Number of subjects: 290
Study 28665377 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment including histamine H2-receptor antagonists, proton pump inhibitors, stimulators of gastrointestinal motility, alginates, and other drugs
Number of subjects: 290
Study 25775048 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal targeted infection program (TIP)
Number of subjects: 418
Study 25775048 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 418
Study 23708720 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation program (n = 52)
Number of subjects: 98
Study 23708720 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (n = 46)
Number of subjects: 98
Study 21348539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc with ritonavir and protease inhibitors (fixed-sequence studies)
Number of subjects: 0
Study 21348539 — intervention group
Group type: COMPARATOR
Intervention: Vicriviroc with or without lopinavir, zidovudine/lamivudine, and tenofovir disoproxil fumarate (parallel-group studies)
Number of subjects: 0
Study 21348539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc with other antiretroviral agents
Number of subjects: 0
Study 21348539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc and combination treatment
Number of subjects: 0
Study 21348539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc co-administered with antiretroviral agents
Number of subjects: 0
Study 18509176 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel therapy in ER-positive patients
Number of subjects: 3329
Study 18509176 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel therapy in ER-negative patients
Number of subjects: 3329
Study 18509176 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel therapy
Number of subjects: 3329
Study 16971709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Lifestyle Program (MLP)
Number of subjects: 279
Study 16971709 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 279
Study 12657917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilantin
Number of subjects: 12
Study 12657917 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsolin
Number of subjects: 12
Study 12657917 — intervention group
Group type: EXPERIMENTAL
Intervention: M-toin
Number of subjects: 12
Study 12657917 — intervention group
Group type: COMPARATOR
Intervention: Eptoin
Number of subjects: 12
Study 10737286 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 20 mg
Number of subjects: 133
Study 10737286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 10737286 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (mean dose approximately 40 mg/d after titration)
Number of subjects: 133
Study 10737286 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 133
Study 8762741 — intervention group
Group type: EXPERIMENTAL
Intervention: District drug formulary
Number of subjects: 50
Study 1412653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 97
Study 1412653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 2881964 — intervention group
Group type: EXPERIMENTAL
Intervention: DN-1417
Number of subjects: 12
Study 2881964 — intervention group
Group type: COMPARATOR
Intervention: DT gamma E
Number of subjects: 12
Study 31300493 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT patches
Number of subjects: 884
Study 31300493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 884
Study 27824661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 4165
Study 27824661 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS)
Number of subjects: 4165
Study 27824661 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 4165
Study 26427305 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80
Study 26427305 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80
Study 23994101 — intervention group
Group type: EXPERIMENTAL
Intervention: First TKA
Number of subjects: 30
Study 23994101 — intervention group
Group type: EXPERIMENTAL
Intervention: Second TKA
Number of subjects: 30
Study 22696995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynesys posterior stabilization
Number of subjects: 53
Study 22696995 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 53
Study 20099349 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid (0.025 mmol/kg body weight)
Number of subjects: 295
Study 20099349 — intervention group
Group type: COMPARATOR
Intervention: Gadobenate dimeglumine (0.05 mmol/kg body weight)
Number of subjects: 295
Study 18050628 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min acupuncture treatment
Number of subjects: 251
Study 18050628 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min acupuncture treatment
Number of subjects: 251
Study 18050628 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min acupuncture treatment
Number of subjects: 251
Study 18050628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (all groups)
Number of subjects: 251
Study 18050628 — intervention group
Group type: COMPARATOR
Intervention: 60 min group vs 20 min and 40 min groups
Number of subjects: 251
Study 18050628 — intervention group
Group type: COMPARATOR
Intervention: 40 min group vs 20 min group
Number of subjects: 251
Study 15929963 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactance (X(rs)) measured by forced oscillometry
Number of subjects: 40
Study 15929963 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactance (X(rs))
Number of subjects: 40
Study 15929963 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted R(L) from X(rs)
Number of subjects: 40
Study 15929963 — intervention group
Group type: EXPERIMENTAL
Intervention: X(rs) in subjects with other respiratory conditions
Number of subjects: 40
Study 12593524 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate (BDP) suspension for nebulization 3,000-4,000 microg/day b.i.d. via nebulizer
Number of subjects: 124
Study 12593524 — intervention group
Group type: COMPARATOR
Intervention: Beclometasone dipropionate (BDP) spray 1,500-2,000 microg/day b.i.d. via metered-dose inhaler (MDI) plus spacer
Number of subjects: 124
Study 12593524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 124
Study 10560993 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic dye (LD) studies
Number of subjects: 278
Study 10560993 — intervention group
Group type: COMPARATOR
Intervention: Selective salpingography (SS)
Number of subjects: 278
Study 8712434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 1 microgram/kg
Number of subjects: 8
Study 8712434 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 1 microgram/kg
Number of subjects: 8
Study 1986567 — intervention group
Group type: COMPARATOR
Intervention: EPO alone (2,000 U IV three times a week)
Number of subjects: 15
Study 1986567 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (2,000 U IV three times a week) + nandrolone decanoate (100 mg IM weekly)
Number of subjects: 15
Study 6834370 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg pindolol
Number of subjects: 30
Study 31338545 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein (CRHP) diet
Number of subjects: 28
Study 31338545 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes (CD) diet
Number of subjects: 28
Study 30428891 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - two sessions
Number of subjects: 162
Study 30428891 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) - typical daily clinical practice
Number of subjects: 162
Study 26873452 — intervention group
Group type: EXPERIMENTAL
Intervention: Food addiction group (after sad mood induction)
Number of subjects: 66
Study 26873452 — intervention group
Group type: EXPERIMENTAL
Intervention: Food addiction group (before sad mood induction)
Number of subjects: 66
Study 26873452 — intervention group
Group type: COMPARATOR
Intervention: Control group (after sad mood induction)
Number of subjects: 66
Study 25262567 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine (DAM) or hydromorphone (HDM)
Number of subjects: 29
Study 25262567 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone maintenance treatment (MMT)
Number of subjects: 29
Study 21798873 — intervention group
Group type: EXPERIMENTAL
Intervention: Home interview
Number of subjects: 450
Study 21798873 — intervention group
Group type: COMPARATOR
Intervention: Research office interview
Number of subjects: 450
Study 20082055 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 576
Study 20082055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 576
Study 17327536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (toileting and walking assistance)
Number of subjects: 145
Study 17327536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 145
Study 14691709 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 517
Study 14691709 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 517
Study 11748952 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised purified flavonoid fraction (MPFF) 500 mg twice daily for 60 days
Number of subjects: 101
Study 11748952 — intervention group
Group type: COMPARATOR
Intervention: Placebo 500 mg twice daily for 60 days
Number of subjects: 101
Study 11748952 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised purified flavonoid fraction (MPFF) in patients with edema
Number of subjects: 101
Study 11748952 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with edema
Number of subjects: 101
Study 9709879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (ABCD) 4 mg/(kg.d)
Number of subjects: 213
Study 9709879 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B 0.8 mg/(kg.d)
Number of subjects: 213
Study 9709879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (ABCD)
Number of subjects: 213
Study 9709879 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 213
Study 7654480 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporin (Neoral), 10 mg kg‐1
Number of subjects: 8
Study 7654480 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral formulation of cyclosporin (Sandimmun), 10 mg kg‐1
Number of subjects: 8
Study 7654480 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporin (Neoral)
Number of subjects: 8
Study 2566161 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 10
Study 2566161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 364615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (50+50+100 mg)
Number of subjects: 28
Study 364615 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (250+250+250 mg)
Number of subjects: 28
Study 364615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 28
Study 364615 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 28
Study 364615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen and Naproxen
Number of subjects: 28
Study 31850976 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings for 7 days
Number of subjects: 206
Study 31850976 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings for 7 days (with concurrent phlebectomies)
Number of subjects: 206
Study 31850976 — intervention group
Group type: COMPARATOR
Intervention: No compression stockings
Number of subjects: 206
Study 31850976 — intervention group
Group type: COMPARATOR
Intervention: Both groups (compression and no compression)
Number of subjects: 206
Study 31850976 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 206
Study 29654563 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste (TAP) with minocycline
Number of subjects: 120
Study 29654563 — intervention group
Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP)
Number of subjects: 120
Study 29654563 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP with amoxicillin
Number of subjects: 120
Study 29654563 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP with cefaclor
Number of subjects: 120
Study 29654563 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP with doxycycline
Number of subjects: 120
Study 29654563 — intervention group
Group type: COMPARATOR
Intervention: No filling (control group)
Number of subjects: 120
Study 29654563 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal bleaching with hydrogen peroxide (H2O2)
Number of subjects: 120
Study 29654563 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal bleaching with H2O2 plus Nd‐YAG laser irradiation
Number of subjects: 120
Study 28162785 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block + systemic analgesia (Group 1)
Number of subjects: 40
Study 28162785 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia (Group 2)
Number of subjects: 40
Study 26275900 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous weight
Number of subjects: 2811
Study 26275900 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in step count
Number of subjects: 2811
Study 26275900 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous weight measurements
Number of subjects: 2811
Study 26275900 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous step count
Number of subjects: 2811
Study 23938028 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg intravenous dexamethasone
Number of subjects: 1350
Study 23938028 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 1350
Study 21810649 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (valproate) at a target dose of 10 to 12 mg per kilogram of body weight per day for 24 months
Number of subjects: 313
Study 21810649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 19265311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg combined with dexamethasone 10 mg
Number of subjects: 50
Study 19265311 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 50
Study 17040215 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg single dose) taken 12 hours prior to melatonin intake
Number of subjects: 12
Study 17040215 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg single dose) taken 24 hours prior to melatonin intake
Number of subjects: 12
Study 17040215 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg orally)
Number of subjects: 12
Study 17040215 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from caffeine for 24 hours prior to melatonin intake
Number of subjects: 12
Study 17040215 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin as a probe drug
Number of subjects: 12
Study 15124980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg and dimenhydrinate 40 mg (Arlevert, ARL)
Number of subjects: 21
Study 15124980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate 50 mg
Number of subjects: 21
Study 15124980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11585005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0
Study 11585005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide + Metformin
Number of subjects: 0
Study 11585005 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 9161648 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobial gel containing cetrimide, bacitracin, and polymyxin B sulfate
Number of subjects: 177
Study 9161648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 9161648 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine antiseptic cream
Number of subjects: 177
Study 7967362 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide alone (50 mg i.v.)
Number of subjects: 10
Study 7967362 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide + Butizid (20 mg i.v.)
Number of subjects: 10
Study 3307643 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of desmopressin given through a nasal pipette
Number of subjects: 30
Study 3307643 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of desmopressin tablet
Number of subjects: 30
Study 3307643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3307643 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (both oral and nasal)
Number of subjects: 30
Study 31786349 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy with salpingectomy
Number of subjects: 86
Study 31786349 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy without salpingectomy (control group)
Number of subjects: 86
Study 31786349 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 86
Study 30098126 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-propionate ester (IPE) 20 g/d for 42 days
Number of subjects: 18
Study 30098126 — intervention group
Group type: COMPARATOR
Intervention: Inulin control
Number of subjects: 18
Study 27381489 — intervention group
Group type: EXPERIMENTAL
Intervention: dGEMRIC
Number of subjects: 32
Study 27381489 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 mapping
Number of subjects: 32
Study 25271185 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg i.m. ketamine
Number of subjects: 48
Study 25271185 — intervention group
Group type: COMPARATOR
Intervention: 10 mg i.m. morphine
Number of subjects: 48
Study 25271185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23710492 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin (5%) applied topically every hour while awake until reepithelialization, then 4 times daily for at least 3 weeks
Number of subjects: 368
Study 23710492 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin (5%)
Number of subjects: 368